Patent · US Active

Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy

US10300074B2 · kind B2 · utility

3Cited by

14References

7Claims

0Family size

Assignees

Inventors

Lars PACHE · Village of La Jolla, US
Sumit Chanda · Village of La Jolla, US
Mitchell Dennis Vamos · San Diego, US
Nicholas David Peter COSFORD · Village of La Jolla, US
Peter TERIETE · Village of La Jolla, US
John M. Marlett · San Diego, US
Arturo Diaz · Village of La Jolla, US
John A. T. Young · Village of La Jolla, US

Key dates

Filing date	Jun 4, 2015
Grant date	May 28, 2019
Priority date	—
Expiry date	Jun 4, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV). Described herein is the use of IAP antagonists in the treatment of human immunodeficiency virus (HIV) in a mammal, alone or in combination with other therapeutic agents used in HIV therapy. In one aspect, provided herein is a method of treating human immunodeficiency virus (HIV) in an individual in need thereof comprising administering a therapeutically effective amount of at least one inhibitor of apoptosis proteins (IAP) antagonist.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.